EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
04 Agosto 2021 - 1:00PM
Business Wire
Collaboration leverages AbCellera’s AI-powered technology
platform to identify novel antibody drug candidates for multiple
disease targets across several therapeutic areas coupled with
EQRx’s innovative model to accelerate the delivery and patient
access to novel medicines at radically lower prices
EQRx, a company committed to developing and delivering important
new medicines at radically lower prices, and AbCellera (Nasdaq:
ABCL), a technology company with a centralized operating system for
next-generation antibody discovery, today announced a collaboration
agreement for the discovery and development of therapeutic
antibodies. The collaboration will leverage AbCellera’s AI-powered
antibody discovery technology to search and analyze natural immune
responses to identify novel antibody drug candidates for multiple
targets. The partnership, which spans several therapeutic areas,
will help to rapidly expand EQRx’s early-stage pipeline of novel
medicines. The deal also includes the option for additional
investment from AbCellera at progressive stages of preclinical
development, clinical development, and commercialization in
exchange for an increased share of product sales. The initial
programs will focus on targets in oncology and immunology.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210804005367/en/
“This collaboration with AbCellera represents another important
step to continue to expand our portfolio as we seek to lead the way
in the future of affordable, accessible and high-impact medicines,”
said Carlos Garcia-Echeverria, Ph.D., chief of Rx creation at EQRx.
“AbCellera’s operating system for antibody discovery addresses each
step in the process to dramatically improve the cycle time, cost,
and probability of success, and we look forward to working together
to advance unique clinical candidates against key disease
targets.”
“AbCellera exists to create value by connecting technology with
innovation of all kinds - innovation in biology, in new drug
modalities, and in new commercial models. We’re proud to partner
with EQRx on their bold mission to reimagine drug development and
bring medicines to patients faster and at lower cost,” said Carl
Hansen, Ph.D., CEO of AbCellera. “This partnership is yet another
example of how we can apply our business model, creating greater
value and alignment through deals that include the option to invest
in programs.”
About EQRx
EQRx is committed to catalyzing a market-based solution to one
of society’s biggest healthcare challenges by developing important
new medicines and offering them at lower prices. Through strategic
partnerships with stakeholders from across the healthcare system
and cutting-edge science and technology, the Company aims to
provide high-quality, patent-protected medicines more efficiently
and cost-effectively than ever before. EQRx is a purpose-built
disruptor at scale, remaking medicine to bend the cost curve in
drug pricing. To learn more, visit www.eqrx.com and follow us on
social media: Twitter: @EQRxInc, LinkedIn, Instagram: @eqrxinc.
EQRx™ and Remaking Medicine™ are trademarks of EQRx, Inc.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce cost, and tackle the toughest problems in drug
development. For more information, please visit www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s beliefs and
assumptions and on information currently available to management.
All statements contained in this release other than statements of
historical fact are forward-looking statements, including
statements regarding our ability to develop, commercialize and
achieve market acceptance of our current and planned products and
services, our research and development efforts, and other matters
regarding our business strategies, use of capital, results of
operations and financial position, and plans and objectives for
future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210804005367/en/
EQRx: Media: Meggan Buckwell; media@EQRx.com
AbCellera: Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236) 521-6774 Business Development: Neil
Berkley; bd@abcellera.com, +1(604) 559-9005 Investor Relations:
Melanie Solomon; ir@abcellera.com, +1(778) 729-9116
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024